Summary
Updated Aug 31, 2026
Richard Chin is Director of Cytek Biosciences, Inc. (CTKB). 6 SEC Form 4 filings on record going back to 2025, most recently on 20 August 2026.
Recent Transactions
5Every recent SEC Form 4 transaction Richard Chin has reported, most recent first.
Other Insiders Active in the Same Sector
No other insider has filed at Richard Chin's companies, so these are insiders reporting open-market trades at other companies in the same sector.
- ULSE Inc. - $146.25M of ULS open-market activity in the last 12 months
- Fairmount Funds Management LLC - $133.53M of APGE open-market activity in the last 12 months
- Jason P. Rhodes - $124.92M of DYN open-market activity in the last 12 months
- Stephen M. Bloch - $118.66M of LQDA open-market activity in the last 12 months
- RA CAPITAL MANAGEMENT, L.P. - $117.62M of ARTV open-market activity in the last 12 months
- SVF Pauling (Cayman) Ltd - $116.40M of RLAY open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Richard Chin?
Richard Chin is a corporate insider, tracked as Director of Cytek Biosciences, Inc. (CTKB). InsiderAlpha holds 6 primary Form 4 filings for them, the earliest from 2025, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Richard Chin submitted recently?
2 primary Form 4 filings in the last 90 days, covering 1 company.
Where can I see all of Richard Chin's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Richard Chin and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
